Call Us for Support
+91 9654860915
Finding access to medicine unapproved in your home country can feel overwhelming. We’re here to help you navigate the process, from your initial request to procurement coordination.
Submit your details and prescription to get started.Register today to get started on your medicine access journey.
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Order Inetetamab on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Inetetamab is an antibody drip for people with HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer). It is given together with the chemotherapy medicine vinorelbine. It was developed and is made in Shanghai by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., a subsidiary of 3SBio Inc., and is sold in China as Cipterbin® (赛普汀).
China's National Medical Products Administration (NMPA) approved it in June 2020, and it was added to China's national reimbursement drug list at the end of that year. The approved use on the Chinese label is:
Only tumours confirmed as HER2-positive qualify: either a strong (3+) result on the immunohistochemistry (IHC) test, or a borderline (2+) IHC result with a positive FISH test. It belongs to our range of imported cancer treatments, and the decision to use it always rests with the treating oncologist.
Some breast cancers make far too much of a growth-signal protein called HER2, which pushes the cells to divide quickly. This medicine is a humanised IgG1 monoclonal antibody that locks onto the outside part of HER2 and blocks that signal. Its Fc region (the tail of the antibody) was engineered to draw in the body's natural killer cells more strongly, a process called antibody-dependent cell-mediated cytotoxicity (ADCC), so the immune system also helps destroy the marked cancer cells.
The Chinese label gives this schedule:
The oncologist works out the exact dose from the patient's weight and decides how long treatment continues.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Boxed warning on the Chinese label: anti-HER2 antibodies can affect the heart, cause infusion and lung reactions, and harm an unborn baby. In the phase 3 study, 225 patients received the combination with vinorelbine, and the figures below compare them with patients on vinorelbine alone.
Who should not use it: anyone allergic to the antibody, its other ingredients or Chinese hamster ovary (CHO) cell proteins. The label also advises against its use in people with heart failure, uncontrolled high-risk rhythm problems, angina needing medicines, significant heart valve disease, an earlier full-thickness heart attack on ECG, or poorly controlled blood pressure.
Pregnancy and breastfeeding: this type of antibody can reduce the fluid around the baby and harm lung development, so a pregnancy during treatment needs close specialist monitoring. Breastfeeding should stop during treatment. Safety under 18 years has not been established, and experience in people over 65 is limited.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
It is imported only in the patient's own name, through the patient or a hospital, under India's rules on importing unapproved medicines. The file normally includes:
Once our team has checked the prescription and the import permit, where one is needed, has been issued.
No. CDSCO has not approved it, and Indian chemists do not stock it. It also has no approval from the US FDA or the European Medicines Agency; its only marketing approval that we could confirm is in China.
An oncologist can still ask for it through the Named Patient Program (NPP), the legal route for importing a medicine that is not registered in India for one named patient. For HER2-positive disease we also help with the Chinese tablet pyrotinib, and for some other breast cancers with sacituzumab tirumotecan.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The label asks for the powder vials to be kept and transported at 2°C to 8°C, protected from light and kept dry, so they travel under temperature-controlled shipping all the way to the hospital. Because the dose is given every week and is based on body weight, we usually send enough 50 mg vials for a full 28-day vinorelbine cycle at a time. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients with HER2-positive metastatic breast cancer anywhere in India can receive this antibody through a regulated import route, delivered cold to the hospital that gives the infusion, on a valid oncologist's prescription.
Breast oncology units in Delhi run weekly day-care drips, and dispatching from New Delhi means each cold box reaches them within hours.
Oncologists in Mumbai can send the HER2 report and weight-based dose, and we work out the vial count before quoting.
For day-care centres in Bangalore, the vials are delivered before the cycle's first infusion day so the vinorelbine schedule is not delayed.
Hospitals in Chennai receive the refrigerated vials with the temperature record attached for their pharmacy to check.
Families in Hyderabad get the full cost for one 28-day cycle in writing before any order is placed.
Shipments to Kolkata and the north-east are packed to hold 2°C to 8°C for the longer journey.
Breast cancer patients in Pune who have finished earlier chemotherapy can use the same documented named-patient route.
The oncologist in Ahmedabad can begin by sharing the biopsy and FISH reports with our pharmacists.
Patients in Jaipur and across Rajasthan can have the vials sent to the hospital that gives their weekly infusion.
Cancer centres in Chandigarh treating patients from Punjab, Haryana and Himachal Pradesh can receive cold-chain deliveries directly.
We coordinate with oncology day-care units in Lucknow so the stock is in the fridge before treatment day.
Patients in Kochi and nearby Kerala towns can have each cycle's vials delivered to their treating hospital.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 November 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message